Literature DB >> 23001607

Non-coding RNAs and EZH2 interactions in cancer: long and short tales from the transcriptome.

Leonidas Benetatos1, Evangelos Voulgaris, George Vartholomatos, Eleftheria Hatzimichael.   

Abstract

A large amount of data indicates that non-coding RNAs represent more than the "dark matter" of the genome. Both microRNAs and long non-coding RNAs are involved in several fundamental biologic processes, and their deregulation may lead in oncogenesis. Interacting with the Polycomb-repressive complex 2 subunit EZH2, they could affect the expression of protein-coding genes and form feedback networks and autoregulatory loops. They can also form networks with upstream and downstream important factors, in which EZH2 represent the stabilizing factor of the pathway. As such non-coding RNAs affect the epigenetic modifications leading to malignant transformation.
Copyright © 2012 UICC.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23001607     DOI: 10.1002/ijc.27859

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  42 in total

Review 1.  Interplay of chromatin modifications and non-coding RNAs in the heart.

Authors:  Prabhu Mathiyalagan; Samuel T Keating; Xiao-Jun Du; Assam El-Osta
Journal:  Epigenetics       Date:  2013-10-10       Impact factor: 4.528

Review 2.  Long non-coding RNAs and MYC association in hematological malignancies.

Authors:  Leonidas Benetatos; Agapi Benetatou; Georgios Vartholomatos
Journal:  Ann Hematol       Date:  2020-07-04       Impact factor: 3.673

3.  Long non-coding RNA CCAT2 promotes gastric cancer proliferation and invasion by regulating the E-cadherin and LATS2.

Authors:  Yong-Jun Wang; Jian-Zhen Liu; Pei Lv; Yi Dang; Jiang-Yan Gao; Yong Wang
Journal:  Am J Cancer Res       Date:  2016-11-01       Impact factor: 6.166

Review 4.  Could lncRNAs be the missing links in control of mesenchymal stem cell differentiation?

Authors:  Coralee E Tye; Jonathan A R Gordon; Lori A Martin-Buley; Janet L Stein; Jane B Lian; Gary S Stein
Journal:  J Cell Physiol       Date:  2015-03       Impact factor: 6.384

Review 5.  Role of EZH2 histone methyltrasferase in melanoma progression and metastasis.

Authors:  Fade Mahmoud; Bradley Shields; Issam Makhoul; Laura F Hutchins; Sara C Shalin; Alan J Tackett
Journal:  Cancer Biol Ther       Date:  2016-04-22       Impact factor: 4.742

6.  Targeting Enhancer of Zeste Homolog 2 as a promising strategy for cancer treatment.

Authors:  Irene Marchesi; Luigi Bagella
Journal:  World J Clin Oncol       Date:  2016-04-10

7.  Long intergenic non-coding RNA 00152 promotes renal cell carcinoma progression by epigenetically suppressing P16 and negatively regulates miR-205.

Authors:  Yongjun Wang; Jianzhen Liu; Hongzhong Bai; Yi Dang; Pei Lv; Shucai Wu
Journal:  Am J Cancer Res       Date:  2017-02-01       Impact factor: 6.166

8.  Long noncoding RNA PVT1 modulates thyroid cancer cell proliferation by recruiting EZH2 and regulating thyroid-stimulating hormone receptor (TSHR).

Authors:  Qinyi Zhou; Jun Chen; Jialin Feng; Jiadong Wang
Journal:  Tumour Biol       Date:  2015-10-01

9.  Gene mutations and molecularly targeted therapies in acute myeloid leukemia.

Authors:  Eleftheria Hatzimichael; Georgios Georgiou; Leonidas Benetatos; Evangelos Briasoulis
Journal:  Am J Blood Res       Date:  2013-01-17

Review 10.  Polycomb group proteins and MYC: the cancer connection.

Authors:  Leonidas Benetatos; George Vartholomatos; Eleftheria Hatzimichael
Journal:  Cell Mol Life Sci       Date:  2013-07-30       Impact factor: 9.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.